S
0.074
0.00 (0.00%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Sangamo Therapeutics, Inc. | 混合的 | 混合的 |
AIStockmoo 评分
| 价值 35% | -5.0 |
| AI Insight 参考 | NA |
| 相对估值 参考 | NA |
| 财务健康 参考 | -5.0 |
| 时机 35% | 0.0 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | 0.0 |
| 技术平均移动指标 参考 | 0.0 |
| 聪明钱 30% | 0.0 |
| 分析师共识 参考 | 0.0 |
| 内部交易活动 参考 | NA |
| 市场环境 | ×1.21 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | -17.9% |
| 支柱一致性 | ×1.00 |
| 不计入评分 | |
| 价格波动 参考 | NA |
| 最终评分 | -2.12 |
|
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington’s Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 2.75% |
| 机构持股比例 | 22.78% |
该时间范围内无数据。
该时间范围内无数据。
投资组合